Indeed, our drop-out rate was consistent with those reported elsewhere (25–74%) [12,13,17,18,21,22]. Of note, many drop-outs involved subjects exposed to an HIV-negative source, a situation in which follow-up testing is not mandatory. Another limitation was the retrospective aspect
of our analysis and the fact that data were limited to those that could be obtained from case note reviews. However, files were often complete and only a minority of nPEP requests could not be analysed because of missing data (7%). PEP prescription in cases of exposure to a source of unknown HIV status is an everyday challenge for most reference centres world-wide. Although available HIV prevalence data for high-risk groups favour the use of prophylaxis in these situations, testing the source person probably represents RG7204 ic50 the best and most cost-effective way to avoid unnecessary exposure to antiviral prophylaxis. It also represents a unique opportunity to screen a difficult-to-reach population engaging in practices carrying a high risk for HIV infection. When the HIV status of the source cannot be determined, the decision to offer prophylaxis should be based on an individual evaluation of risk factors given the high prevalence of undiagnosed HIV infection in this population.
We thank Serge Gallant, Sophie Farine, Véronique Fardel, Talazoparib chemical structure Véronique Nicklas and Vreneli Waelti for their indispensable help in collecting clinical data throughout the study period. Author contributions: F.T. had full access to all data and takes responsibility for the accuracy of the data analysis. M.C. was responsible for the concept and design of the study. F.T. analysed the data and drafted the manuscript. M.C., V.E. and T.D. were involved in critical revision of the manuscript. V.E. provided statistical expertise. Financial support:
None. Potential conflicts of interest: F.T. has received travel grants from Tibotec/Janssen-Cilag AG. T.D. has received travel grants from Merck Sharp & Dohme and Tibotec/Janssen-Cilag AG. M.C. has received travel grants Orotidine 5′-phosphate decarboxylase from Abbott, Boehringer-Ingelheim, Gilead and Roche. V.E. has no conflict of interest. “
“The aim of the study was to investigate the effect of long-term high-physiological-dose recombinant human growth hormone (rhGH) therapy on fat distribution and glucose metabolism in HIV-infected patients. Forty-six HIV-infected Caucasian men on highly active antiretroviral therapy (HAART), with an age range of 21–60 years and no significant comorbidity, were included in this randomized, placebo-controlled, double-blind, single-centre trial. Twenty-eight subjects were randomized to 0.7 mg/day rhGH, and 18 subjects to placebo, administered as daily subcutaneous injections between 1 and 3 pm for 40 weeks.